Adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet, as well as resolution on disposal of profits and discharge from liability

The meeting resolved to adopt the profit and loss statement and balance sheet for the financial year 2018 and, in accordance with the board of directors' proposal and the auditor's recommendation, that the Company's accumulated profits shall be carried forward into new account.

The meeting resolved to discharge the members of the board of directors and the CEO from liability for the financial year 2018.

Determination of the fees payable to the members of the board of directors and the auditor

The meeting resolved that fees payable to the board of directors for the period until the end of the next annual general meeting shall amount to a total of SEK 625,000, out of which SEK 325,000 shall be paid to the chairman, SEK 100,000 shall be paid to the board member Eva Walde and SEK 50,000 shall be paid to each of the remaining board members. The meeting further resolved that the Company's auditor shall be paid in accordance with approved invoices, within the frames of the quote.

Election of board members and auditor 

Thomas Eklund, Sten Gibeck, Bengt Julander, Ola Magnusson, Michael Ryan and Eva Walde were re-elected as board members and Thomas Eklund was re-elected as chairman of the board of directors for the period until the end of the next annual general meeting. Christina Kallin Sharpe was re-elected as auditor and Caroline Ljungberg as deputy auditor for the period until the end of the next annual general meeting.

Resolution on principles for the appointment of and instructions for the nomination committee

The meeting resolved to adopt principles for the appointment of and instructions for the nomination committee.

Resolution on an authorisation for the board of directors to issue new shares

The meeting resolved to authorise the board of directors to, with or without deviation from the shareholders' preferential rights, resolve on new issues of shares which, in aggregate, do not exceed 15 percent of the total number of shares outstanding after exercise of the authorisation, based on the number of shares outstanding in the Company at the time when the authorisation is first exercised. The purpose of the authorisation is to provide the board of directors with flexibility in its work to ensure that the Company can be contributed with capital for the financing of the business in an appropriate manner, to effect business or product acquisitions, and/or to enable the Company's ownership base to be broadened.

Resolution on incentive programme 2019/2022 for employees and consultants by way of directed issue of warrants to a subsidiary for subsequent transfer to the participants

The meeting resolved to establish incentive programme 2019/2022 for employees and consultants, including a directed issue of no more than 370,000 warrants of series 2019/2022 to the Company's subsidiary Sedana Medical Incentive AB, for subsequent transfer to the participants in the incentive programme. The purpose of the incentive programme is to establish conditions to recruit and maintain qualified personnel in the group and to increase the motivation of the co-workers and stimulate an increased interest for the business and earnings of the Company. Upon exercise of all warrants of series 2019/2022, the share capital of the Company will be increased by SEK 37,000.

For additional information, please contact:
Christer Ahlberg, CEO, Sedana Medical AB
Mobile: +46 70 675 33 30
E-mail: christer.ahlberg@sedanamedical.com

Sedana Medical is listed on Nasdaq First North in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

_____________________________________

Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. A major clinical registration study is currently ongoing to obtain market approval in Europe for inhalation sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane).

Sedana Medical has direct sales in the Nordic countries, Germany, France, Great Britain and Spain as well as external distributors in the rest of Europe, Canada, Australia, Japan and South Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in Ireland.